|
gptkbp:instanceOf
|
gptkb:chemical_compound
sedative
|
|
gptkbp:antidote
|
flumazenil (limited efficacy)
|
|
gptkbp:ATCCode
|
N05CF01
|
|
gptkbp:bioavailability
|
~80% (oral)
|
|
gptkbp:brand
|
gptkb:Imovane
gptkb:Zimovane
gptkb:Zopitan
|
|
gptkbp:CASNumber
|
43200-80-2
|
|
gptkbp:chemicalFormula
|
contains a pyrrolopyrazine ring
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Rhône-Poulenc
|
|
gptkbp:drugClass
|
cyclopyrrolone
|
|
gptkbp:eliminationHalfLife
|
about 5 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C17H17ClN6O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zopiclone
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
CYP3A4 inhibitors
|
|
gptkbp:IUPACName
|
gptkb:6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl_4-methylpiperazine-1-carboxylate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1986
|
|
gptkbp:mechanismOfAction
|
modulates GABA-A receptor
|
|
gptkbp:meltingPoint
|
178–180 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children
pregnancy
breastfeeding
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
~45%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1092
5738
5534
|
|
gptkbp:riskFactor
|
tolerance
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
dizziness
headache
drowsiness
dry mouth
bitter taste
|
|
gptkbp:UNII
|
UHS5N8K95T
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:Nonbenzodiazepine_hypnotics
|
|
gptkbp:bfsLayer
|
6
|